These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 18758781

  • 1. Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
    Metzgeroth G, Dinter D, Schultheis B, Dorn-Beineke A, Lutz K, Leismann O, Hehlmann R, Hastka J.
    Ann Hematol; 2009 Apr; 88(4):301-10. PubMed ID: 18758781
    [Abstract] [Full Text] [Related]

  • 2. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

  • 3. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.
    Greenberg PL, Koller CA, Cabantchik ZI, Warsi G, Glynos T, Paley C, Schiffer C.
    Leuk Res; 2010 Dec; 34(12):1560-5. PubMed ID: 20615548
    [Abstract] [Full Text] [Related]

  • 4. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [Abstract] [Full Text] [Related]

  • 5. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
    Cermak J, Jonasova A, Vondrakova J, Cervinek L, Belohlavkova P, Neuwirtova R.
    Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
    [Abstract] [Full Text] [Related]

  • 6. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
    Cheong JW, Kim HJ, Lee KH, Yoon SS, Lee JH, Park HS, Kim HY, Shim H, Seong CM, Kim CS, Chung J, Hyun MS, Jo DY, Jung CW, Sohn SK, Yoon HJ, Kim BS, Joo YD, Park CY, Min YH, Korean Society of Hematology Acute Myeloid Leukemia/Myelodysplastic Syndrome Working Party.
    Transfusion; 2014 Jun; 54(6):1542-51. PubMed ID: 24313463
    [Abstract] [Full Text] [Related]

  • 7. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
    Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D.
    Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of deferasirox in myelodysplastic syndromes.
    Breccia M, Alimena G.
    Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
    [Abstract] [Full Text] [Related]

  • 9. Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
    Gattermann N, Jarisch A, Schlag R, Blumenstengel K, Goebeler M, Groschek M, Losem C, Procaccianti M, Junkes A, Leismann O, Germing U.
    Eur J Haematol; 2012 Mar; 88(3):260-8. PubMed ID: 22023452
    [Abstract] [Full Text] [Related]

  • 10. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome.
    OKABE H, SUZUKI T, OMORI T, MORI M, UEHARA E, HATANO K, UEDA M, MATSUYAMA T, TOSHIMA M, QZAKI K, NAGAI T, MUROI K, OZAWA K.
    Rinsho Ketsueki; 2009 Nov; 50(11):1626-9. PubMed ID: 20009438
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
    Chang HH, Lu MY, Liao YM, Lin PC, Yang YL, Lin DT, Chiou SS, Jou ST, Lin KH, Chang TT.
    Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy and safety of deferasirox.
    Cappellini MD.
    Blood Rev; 2008 Dec; 22 Suppl 2():S35-41. PubMed ID: 19059055
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
    Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C, EPIC study investigators.
    Leuk Res; 2010 Sep; 34(9):1143-50. PubMed ID: 20451251
    [Abstract] [Full Text] [Related]

  • 16. Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.
    Escudero-Vilaplana V, Garcia-Gonzalez X, Osorio-Prendes S, Romero-Jimenez RM, Sanjurjo-Saez M.
    J Clin Pharm Ther; 2016 Feb; 41(1):59-63. PubMed ID: 26778738
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S, Ebadi M, Ghazizadeh F, Arzanian MT, Shamsian B, Abdollah Gorji F.
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.